Gene Therapy Phase 2 Licensing Benchmarks
Deal economics across 10 transactions with 8 disclosed upfront payments. Primary-source-verified from SEC EDGAR, FTC filings, and direct research.
Median Upfront
$170M
8 deals with terms
Median Total Value
$950M
Upfront + milestones
Royalty Range
7.6%--15.6%
Average low--high
Deal Count
10
2019--2024
The median upfront payment for phase 2 gene therapy licensing deals is $170M, based on 8 deals with disclosed terms from 2019--2024. Total deal values (including milestones) reach a median of $950M. Royalty rates typically range from 7.6% to 15.6%. All data is primary-source-verified from SEC EDGAR, FTC pre-merger filings, and company press releases.
Representative Transactions
| Licensor | Licensee | Year | Upfront | Total Value |
|---|---|---|---|---|
| REGENXBIO | Roche | 2022 | $80M | $1.5B |
| Rocket Pharmaceuticals | Beacon Therapeutics | 2023 | $45M | $400M |
| Taysha Gene Therapies, Inc. | Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) | 2022 | $20M | -- |
Full gene-therapy phase-2 Comp Set
Get the complete analysis -- 8 deals with upfronts, milestones, royalties, and term structures.
Primary-source-verified from SEC EDGAR, FTC filings, and direct research
Run Your Own Analysis
Get a customized deal estimate for your specific gene therapy asset with our proprietary calculator.
Start CalculatingMethodology
This analysis draws from the Ambrosia Ventures proprietary deal database (1,600+ verified biopharma transactions, 2019--2024). All deal terms are primary-source-verified from SEC EDGAR (10-K, 10-Q, 8-K filings), FTC pre-merger notifications, FDA Orange Book, and company press releases. No secondary-source or scraped data is included. Medians are calculated from deals with disclosed financial terms only.